This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in Store for Jounce (JNCE) This Earnings Season?
by Zacks Equity Research
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
Is Jounce Therapeutics (JNCE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (JNCE) Outperforming Other Medical Stocks This Year?
ImmunoGen (IMGN) Looks Good: Stock Adds 7.6% in Session
by Zacks Equity Research
ImmunoGen (IMGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
5 Russell 2000 Stocks That Crushed the Index This Year
by Kaibalya Pravo Dey
Slowing trade conflicts and rate cuts by the Federal Reserve boost the domestic economy. The trend is expected to continue in the next year.
Pacira's Late-Stage Study on Exparel Label Expansion Positive
by Zacks Equity Research
Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.
Assertio to Divest Shingles Pain Drug to Alvogen for $127.5M
by Zacks Equity Research
Assertio (ASRT) inks a deal to sell Gralise to Alvogen for a total value of $127.5 million.
The Zacks Analyst Blog Highlights: Jounce Therapeutics, Forterra, Hibbett Sports, Foundation Building Materials and Orion Energy Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jounce Therapeutics, Forterra, Hibbett Sports, Foundation Building Materials and Orion Energy Systems
Is the Options Market Predicting a Spike in Jounce Therapeutics (JNCE) Stock?
by Zacks Equity Research
Investors need to pay close attention to Jounce Therapeutics (JNCE) stock based on the movements in the options market lately.
Small Business Optimism Rises Amid Trade Jitters: 5 Top Picks
by Nalak Das
A section of the U.S. business community - the small business segment - seems optimistic about the future despite trade-related hiccups.
Jounce Therapeutics, Inc. (JNCE) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Jounce Therapeutics, Inc. (JNCE).
Top Ranked Momentum Stocks to Buy for December 2nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 2nd
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
by Sweta Killa
Healthcare bounced back with an outperformance starting the fourth quarter.
Value ETFs & Stocks Offering Real Value: 5 Top Picks
by Sanghamitra Saha
A favorable operating backdrop and cheap valuation are leading value stocks higher. Play the trend with these cheap value stocks and ETFs.
5 High-Beta ETFs & Stocks for a Record Market
by Sweta Killa
While every corner of the market is enjoying the current ascent, high-beta ETFs and stocks seem a perfect bet at present.
New Strong Buy Stocks for November 11th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Jounce Therapeutics, Inc. (JNCE) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 28.89% and 19.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Value Stocks to Buy for October 29th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, October 29th
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 19.23% and 2.08%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
by Zacks Equity Research
Key highlights of the past week include earnings update, collaborations and other pipeline news.
Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -22.58% and -25.55%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Jounce Therapeutics, Inc. (JNCE) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jounce Therapeutics, Inc. (JNCE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Jounce Therapeutics, Inc. (JNCE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?